Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells $302,936.26 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jereme Sylvain sold 3,638 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the completion of the sale, the executive vice president directly owned 146,828 shares in the company, valued at approximately $12,226,367.56. The trade was a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Price Performance

Shares of DXCM opened at $87.34 on Thursday. The business’s 50-day moving average is $83.52 and its two-hundred day moving average is $73.07. The company has a market capitalization of $32.96 billion, a P/E ratio of 34.52, a P/E/G ratio of 1.45 and a beta of 1.42. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $92.59. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company’s revenue was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.48 earnings per share. Research analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a report on Friday, July 31st. Mizuho increased their price target on shares of DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. TD Cowen restated a “buy” rating on shares of DexCom in a research report on Friday, July 31st. Citigroup reiterated a “buy” rating and issued a $88.00 price objective (up from $84.00) on shares of DexCom in a research report on Friday, July 31st. Finally, BTIG Research reissued a “buy” rating and set a $90.00 target price (up from $80.00) on shares of DexCom in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average target price of $88.71.

Hedge Funds Weigh In On DexCom

A number of large investors have recently added to or reduced their stakes in the stock. Sequoia Financial Advisors LLC lifted its holdings in DexCom by 15.1% during the second quarter. Sequoia Financial Advisors LLC now owns 19,116 shares of the medical device company’s stock valued at $1,287,000 after purchasing an additional 2,509 shares in the last quarter. Tidal Investments LLC increased its stake in shares of DexCom by 6.5% during the second quarter. Tidal Investments LLC now owns 65,922 shares of the medical device company’s stock worth $4,440,000 after purchasing an additional 3,995 shares in the last quarter. Van Hulzen Asset Management LLC purchased a new stake in shares of DexCom during the second quarter worth about $230,000. Scholtz & Company LLC raised its position in shares of DexCom by 12.7% during the 2nd quarter. Scholtz & Company LLC now owns 77,334 shares of the medical device company’s stock worth $5,208,000 after purchasing an additional 8,686 shares during the last quarter. Finally, National Pension Service raised its position in shares of DexCom by 3.9% during the 2nd quarter. National Pension Service now owns 660,309 shares of the medical device company’s stock worth $44,472,000 after purchasing an additional 24,756 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Key DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Expanded leadership role: CFO Jereme Sylvain will also serve as chief operating officer, potentially improving coordination between DexCom’s financial and operational functions as the company expands its continuous glucose-monitoring business. DexCom CFO Jereme Sylvain to Take Additional Role of COO
• Positive Sentiment: Strong recent financial results: DexCom’s latest quarterly report exceeded expectations, with earnings per share of $0.70 versus the $0.61 consensus estimate and revenue of $1.31 billion versus $1.29 billion expected. Revenue increased 13.1% year over year, supporting the growth outlook for its G7 and other CGM products.
• Positive Sentiment: Generally favorable analyst view: The stock carries a “Moderate Buy” consensus rating, with recent bullish targets including $95 from Stifel, $96 from UBS and $105 from Robert W. Baird. The average published target is $88.71, suggesting relatively limited but still positive upside based on the cited estimates.
• Neutral Sentiment: Insider selling appears scheduled: EVP Michael Brown sold 1,700 shares, while Director Nicholas Augustinos sold a combined 8,089 shares. Because the transactions were conducted under pre-arranged trading plans, they may reflect routine diversification rather than a negative view of DexCom’s prospects. DexCom insider transaction filing
• Negative Sentiment: Multiple insider sales could weigh on sentiment: The recent sales, including EVP Jereme Sylvain’s disposal of 3,638 shares for approximately $303,000, add a short-term cautionary signal even though the executives retained substantial holdings. DexCom insider selling report

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.